Mironid Series A funding
Mironid Announces Closing of £4.3 million Series A Financing
Mironid Ltd, a leader in cell signalling directed drug development, that was co-founded by Dr Paul Rodgers of Ithaka Life Sciences, Prof Miles Houslay and colleagues, today announced the closing of its Series A funding round of £4.3 million, which will support the Company’s internal research and preclinical development programmes, focused on degenerative kidney disease, major inflammatory disease and cancer. The funding round was led by Epidarex Capital. The Scottish Investment Bank, on behalf of Scottish Enterprise, and the University of Strathclyde also participated in the round.
Download - ithaka-mironid-press-release-160620.pdf